search
Back to results

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

Primary Purpose

Obesity, Diabetes Mellitus, Type 2

Status
Active
Phase
Phase 3
Locations
International
Study Type
Interventional
Intervention
Semaglutide
Semaglutide
Placebo
Sponsored by
Novo Nordisk A/S
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Obesity

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Male or female. Age above or equal to 18 years at the time of signing informed consent. BMI greater than or equal to 30.0 kilograms per square meter (kg/m^2). Diagnosed with type 2 diabetes (T2D) greater than or equal to 180 days prior to the day of screening. History of at least one self-reported unsuccessful dietary effort to lose body weight. HbA1c 7.0-10.0 percent (53-86 millimoles per mole [mmol/mol]) (both inclusive) as measured by central laboratory at screening. Exclusion Criteria: A self-reported change in body weight greater than 5 kilograms (kg) (11 pounds [lbs]) within 90 days before screening irrespective of medical records. Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma. Renal impairment with estimated Glomerular Filtration Rate (eGFR) less than 30 milliliters per minute per 1.73 square meter (30 mL/min/1.73 m^2) (less than 45 mL/min/1.73 m^2 in participants treated with Sodium-glucose Cotransporter-2 [SGLT2i]) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation as defined by Kidney Disease: Improving Global Outcomes (KDIGO) 2012 by the central laboratory at screening. Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomization. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.

Sites / Locations

  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site
  • Novo Nordisk Investigational Site

Arms of the Study

Arm 1

Arm 2

Arm 3

Arm Type

Experimental

Experimental

Placebo Comparator

Arm Label

Semaglutide 7.2 mg

Semaglutide 2.4 mg

Placebo

Arm Description

Participants will receive once-weekly injection of semaglutide subcutaneously (s.c.) in 20 week dose escalation period with dose escalation (0.25 milligram [mg], 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks until week 72.

Participants will receive once-weekly s.c. injection of semaglutide in 20 week dose escalation period with dose escalation (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week until maintenance dose of 2.4 mg of semaglutide was reached. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 72.

Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks.

Outcomes

Primary Outcome Measures

Semaglutide 7.2 mg versus Placebo: Relative change in body weight
Measured in percentage (%).
Semaglutide 7.2 mg versus Placebo: Number of participants who achieve body weight reduction greater than or equal to (>=) 5% (yes/no)
Measured as count of participants.

Secondary Outcome Measures

Semaglutide 7.2 mg versus Placebo: Number of participants who achieve body weight reduction >=10% (yes/no)
Measured as count of participants.
Semaglutide 7.2 mg versus Placebo: Number of participants who achieve body weight reduction >=15% (yes/no)
Measured as count of participants.
Semaglutide 7.2 mg versus Placebo: Number of participants who achieve body weight reduction >=20% (yes/no)
Measured as count of participants.
Semaglutide 7.2 mg versus Placebo: Change in waist circumference
Measured in centimeters (cm).
Semaglutide 7.2 mg versus Placebo: Change in glycated haemoglobin (HbA1c)
Measured in percentage (%).
Semaglutide 7.2 mg versus Placebo: Change in body weight
Measured in kilograms (kg).
Semaglutide 7.2 mg versus Placebo: Change in body mass index (BMI)
Measured in kilograms per square meter (kg/m^2).
Semaglutide 7.2 mg versus Placebo: Change in systolic blood pressure
Measured in millimeters of mercury (mmHg).
Semaglutide 7.2 mg versus Placebo: Change in diastolic blood pressure
Measured in mmHg.
Semaglutide 7.2 mg versus Placebo: Change in total cholesterol
Measured in ratio to baseline.
Semaglutide 7.2 mg versus Placebo: Change in high-density lipoprotein (HDL) cholesterol
Measured in ratio to baseline.
Semaglutide 7.2 mg versus Placebo: Change in low-density lipoprotein (LDL) cholesterol
Measured in ratio to baseline.
Semaglutide 7.2 mg versus Placebo: Change in very-low-density lipoprotein (VLDL) cholesterol
Measured in ratio to baseline.
Semaglutide 7.2 mg versus Placebo: Change in triglycerides
Measured in ratio to baseline.
Semaglutide 7.2 mg versus Placebo: Change in free fatty acids
Measured in ratio to baseline.
Semaglutide 7.2 mg versus Placebo: Change in high-sensitivity c reactive protein (hsCRP)
Measured in ratio to baseline.
Semaglutide 7.2 mg versus Placebo: Change in fasting plasma glucose
Measured in milligrams per deciliter (mg/dL).
Semaglutide 7.2 mg versus Placebo: Change in fasting serum insulin
Measured in ratio to baseline.
Semaglutide 7.2 mg versus Placebo: Number of participants with HbA1c less than (<) 7.0% (53 millimoles per mole [mmol/mol])
Measured as count of participants.
Semaglutide 7.2 mg versus Placebo: Number of participants with HbA1c less than or equal to (<=) 6.5 % (48 mmol/mol)
Measured as count of participants.
Semaglutide 7.2 mg versus Placebo: Number of adverse events (AEs)
Measured as count of events.
Semaglutide 7.2 mg versus Placebo: Number of serious adverse events (SAEs)
Measured as count of events.
Semaglutide 7.2 mg versus Placebo: Change in pulse
Measured in beats per minute (bpm).
Semaglutide 7.2 mg versus Placebo: Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes
Measured as count of episodes.
Semaglutide 7.2 mg versus Semaglutide 2.4 mg: Number of AEs
Measured as count of events.
Semaglutide 7.2 mg versus Semaglutide 2.4 mg: Number of SAEs
Measured as count of events.
Semaglutide 7.2 mg versus Semaglutide 2.4 mg: Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes
Measured as count of episodes.

Full Information

First Posted
December 5, 2022
Last Updated
July 12, 2023
Sponsor
Novo Nordisk A/S
search

1. Study Identification

Unique Protocol Identification Number
NCT05649137
Brief Title
A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight
Official Title
Effect and Safety of Semaglutide 7.2 mg Once-weekly in Participants With Obesity and Type 2 Diabetes
Study Type
Interventional

2. Study Status

Record Verification Date
July 2023
Overall Recruitment Status
Active, not recruiting
Study Start Date
January 4, 2023 (Actual)
Primary Completion Date
October 4, 2024 (Anticipated)
Study Completion Date
December 6, 2024 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Novo Nordisk A/S

4. Oversight

Studies a U.S. FDA-regulated Drug Product
Yes
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
This study will look at how much weight participants will lose and how much blood sugar control they achieve from the start to the end of the study. The weight loss in participants taking the investigational high dose of semaglutide will be compared to the weight loss in people taking "dummy" medicine and a lower dose of semaglutide. In addition to taking the medicine, participants will have talks with study staff about healthy food choices and how to be more physically active. Participants will either get semaglutide or "dummy" medicine. Which treatment participants get is decided by chance. Participants are more likely (4 out of 5) to get semaglutide than the "dummy" medicine. The study medicine will be injected briefly, under skin, with a thin needle, typically in the stomach, thighs, or upper arms. After receiving first dose, the dose of semaglutide will be gradually increased until reaching the target dose. The study will last for about 1.5 years.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Obesity, Diabetes Mellitus, Type 2

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 3
Interventional Study Model
Parallel Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
513 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Semaglutide 7.2 mg
Arm Type
Experimental
Arm Description
Participants will receive once-weekly injection of semaglutide subcutaneously (s.c.) in 20 week dose escalation period with dose escalation (0.25 milligram [mg], 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg, and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks until week 72.
Arm Title
Semaglutide 2.4 mg
Arm Type
Experimental
Arm Description
Participants will receive once-weekly s.c. injection of semaglutide in 20 week dose escalation period with dose escalation (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week until maintenance dose of 2.4 mg of semaglutide was reached. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks until week 72.
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks.
Intervention Type
Drug
Intervention Name(s)
Semaglutide
Intervention Description
Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg and 7.2 mg) every fourth week. Treatment will be continued on the maintenance dose of 7.2 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Intervention Type
Drug
Intervention Name(s)
Semaglutide
Intervention Description
Participants will receive once-weekly s.c. injections of semaglutide in escalating doses (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, and 2.4 mg) every fourth week. Treatment will be continued on the maintenance dose of 2.4 mg once-weekly for an additional 52 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Intervention Type
Drug
Intervention Name(s)
Placebo
Intervention Description
Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Primary Outcome Measure Information:
Title
Semaglutide 7.2 mg versus Placebo: Relative change in body weight
Description
Measured in percentage (%).
Time Frame
From baseline (week 0) to end of treatment (week 72)
Title
Semaglutide 7.2 mg versus Placebo: Number of participants who achieve body weight reduction greater than or equal to (>=) 5% (yes/no)
Description
Measured as count of participants.
Time Frame
From baseline (week 0) to end of treatment (week 72)
Secondary Outcome Measure Information:
Title
Semaglutide 7.2 mg versus Placebo: Number of participants who achieve body weight reduction >=10% (yes/no)
Description
Measured as count of participants.
Time Frame
From baseline (week 0) to end of treatment (week 72)
Title
Semaglutide 7.2 mg versus Placebo: Number of participants who achieve body weight reduction >=15% (yes/no)
Description
Measured as count of participants.
Time Frame
From baseline (week 0) to end of treatment (week 72)
Title
Semaglutide 7.2 mg versus Placebo: Number of participants who achieve body weight reduction >=20% (yes/no)
Description
Measured as count of participants.
Time Frame
From baseline (week 0) to end of treatment (week 72)
Title
Semaglutide 7.2 mg versus Placebo: Change in waist circumference
Description
Measured in centimeters (cm).
Time Frame
From baseline (week 0) to end of treatment (week 72)
Title
Semaglutide 7.2 mg versus Placebo: Change in glycated haemoglobin (HbA1c)
Description
Measured in percentage (%).
Time Frame
From baseline (week 0) to end of treatment (week 72)
Title
Semaglutide 7.2 mg versus Placebo: Change in body weight
Description
Measured in kilograms (kg).
Time Frame
From baseline (week 0) to end of treatment (week 72)
Title
Semaglutide 7.2 mg versus Placebo: Change in body mass index (BMI)
Description
Measured in kilograms per square meter (kg/m^2).
Time Frame
From baseline (week 0) to end of treatment (week 72)
Title
Semaglutide 7.2 mg versus Placebo: Change in systolic blood pressure
Description
Measured in millimeters of mercury (mmHg).
Time Frame
From baseline (week 0) to end of treatment (week 72)
Title
Semaglutide 7.2 mg versus Placebo: Change in diastolic blood pressure
Description
Measured in mmHg.
Time Frame
From baseline (week 0) to end of treatment (week 72)
Title
Semaglutide 7.2 mg versus Placebo: Change in total cholesterol
Description
Measured in ratio to baseline.
Time Frame
From baseline (week 0) to end of treatment (week 72)
Title
Semaglutide 7.2 mg versus Placebo: Change in high-density lipoprotein (HDL) cholesterol
Description
Measured in ratio to baseline.
Time Frame
From baseline (week 0) to end of treatment (week 72)
Title
Semaglutide 7.2 mg versus Placebo: Change in low-density lipoprotein (LDL) cholesterol
Description
Measured in ratio to baseline.
Time Frame
From baseline (week 0) to end of treatment (week 72)
Title
Semaglutide 7.2 mg versus Placebo: Change in very-low-density lipoprotein (VLDL) cholesterol
Description
Measured in ratio to baseline.
Time Frame
From baseline (week 0) to end of treatment (week 72)
Title
Semaglutide 7.2 mg versus Placebo: Change in triglycerides
Description
Measured in ratio to baseline.
Time Frame
From baseline (week 0) to end of treatment (week 72)
Title
Semaglutide 7.2 mg versus Placebo: Change in free fatty acids
Description
Measured in ratio to baseline.
Time Frame
From baseline (week 0) to end of treatment (week 72)
Title
Semaglutide 7.2 mg versus Placebo: Change in high-sensitivity c reactive protein (hsCRP)
Description
Measured in ratio to baseline.
Time Frame
From baseline (week 0) to end of treatment (week 72)
Title
Semaglutide 7.2 mg versus Placebo: Change in fasting plasma glucose
Description
Measured in milligrams per deciliter (mg/dL).
Time Frame
From baseline (week 0) to end of treatment (week 72)
Title
Semaglutide 7.2 mg versus Placebo: Change in fasting serum insulin
Description
Measured in ratio to baseline.
Time Frame
From baseline (week 0) to end of treatment (week 72)
Title
Semaglutide 7.2 mg versus Placebo: Number of participants with HbA1c less than (<) 7.0% (53 millimoles per mole [mmol/mol])
Description
Measured as count of participants.
Time Frame
From baseline (week 0) to end of treatment (week 72)
Title
Semaglutide 7.2 mg versus Placebo: Number of participants with HbA1c less than or equal to (<=) 6.5 % (48 mmol/mol)
Description
Measured as count of participants.
Time Frame
From baseline (week 0) to end of treatment (week 72)
Title
Semaglutide 7.2 mg versus Placebo: Number of adverse events (AEs)
Description
Measured as count of events.
Time Frame
From baseline (week 0) to end of study (week 81)
Title
Semaglutide 7.2 mg versus Placebo: Number of serious adverse events (SAEs)
Description
Measured as count of events.
Time Frame
From baseline (week 0) to end of study (week 81)
Title
Semaglutide 7.2 mg versus Placebo: Change in pulse
Description
Measured in beats per minute (bpm).
Time Frame
From baseline (week 0) to end of treatment (week 72)
Title
Semaglutide 7.2 mg versus Placebo: Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes
Description
Measured as count of episodes.
Time Frame
From baseline (week 0) to end of study (week 81)
Title
Semaglutide 7.2 mg versus Semaglutide 2.4 mg: Number of AEs
Description
Measured as count of events.
Time Frame
From baseline (week 0) to end of study (week 81)
Title
Semaglutide 7.2 mg versus Semaglutide 2.4 mg: Number of SAEs
Description
Measured as count of events.
Time Frame
From baseline (week 0) to end of study (week 81)
Title
Semaglutide 7.2 mg versus Semaglutide 2.4 mg: Number of treatment emergent severe or blood glucose confirmed symptomatic hypoglycaemic episodes
Description
Measured as count of episodes.
Time Frame
From baseline (week 0) to end of study (week 81)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male or female. Age above or equal to 18 years at the time of signing informed consent. BMI greater than or equal to 30.0 kilograms per square meter (kg/m^2). Diagnosed with type 2 diabetes (T2D) greater than or equal to 180 days prior to the day of screening. History of at least one self-reported unsuccessful dietary effort to lose body weight. HbA1c 7.0-10.0 percent (53-86 millimoles per mole [mmol/mol]) (both inclusive) as measured by central laboratory at screening. Exclusion Criteria: A self-reported change in body weight greater than 5 kilograms (kg) (11 pounds [lbs]) within 90 days before screening irrespective of medical records. Personal or first-degree relative(s) history of multiple endocrine neoplasia type 2 or medullary thyroid carcinoma. Renal impairment with estimated Glomerular Filtration Rate (eGFR) less than 30 milliliters per minute per 1.73 square meter (30 mL/min/1.73 m^2) (less than 45 mL/min/1.73 m^2 in participants treated with Sodium-glucose Cotransporter-2 [SGLT2i]) according to Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) creatinine equation as defined by Kidney Disease: Improving Global Outcomes (KDIGO) 2012 by the central laboratory at screening. Uncontrolled and potentially unstable diabetic retinopathy or maculopathy. Verified by a fundus examination performed within 90 days before screening or in the period between screening and randomization. Pharmacological pupil-dilation is a requirement unless using a digital fundus photography camera specified for non-dilated examination.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Clinical Transparency (dept. 2834)
Organizational Affiliation
Novo Nordisk A/S
Official's Role
Study Director
Facility Information:
Facility Name
Novo Nordisk Investigational Site
City
Birmingham
State/Province
Alabama
ZIP/Postal Code
35222
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Montgomery
State/Province
Alabama
ZIP/Postal Code
36106
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Concord
State/Province
California
ZIP/Postal Code
94520
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Los Angeles
State/Province
California
ZIP/Postal Code
90057
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Walnut Creek
State/Province
California
ZIP/Postal Code
94598
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Golden
State/Province
Colorado
ZIP/Postal Code
80401
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
DeLand
State/Province
Florida
ZIP/Postal Code
32720
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Jacksonville
State/Province
Florida
ZIP/Postal Code
32216
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Orlando
State/Province
Florida
ZIP/Postal Code
32825
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Oviedo
State/Province
Florida
ZIP/Postal Code
32765
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Conyers
State/Province
Georgia
ZIP/Postal Code
30094
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Chapel Hill
State/Province
North Carolina
ZIP/Postal Code
27514
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Greensboro
State/Province
North Carolina
ZIP/Postal Code
27408
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Amarillo
State/Province
Texas
ZIP/Postal Code
79106
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Austin
State/Province
Texas
ZIP/Postal Code
78704
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75230
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Houston
State/Province
Texas
ZIP/Postal Code
77079
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Longview
State/Province
Texas
ZIP/Postal Code
75605
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Sugar Land
State/Province
Texas
ZIP/Postal Code
77479
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Richmond
State/Province
Virginia
ZIP/Postal Code
23294
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Winchester
State/Province
Virginia
ZIP/Postal Code
22601-3834
Country
United States
Facility Name
Novo Nordisk Investigational Site
City
Blagoevgrad
ZIP/Postal Code
2700
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Burgas
ZIP/Postal Code
8000
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Dobrich
ZIP/Postal Code
9300
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Pazardzhik
ZIP/Postal Code
4400
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Plovdiv
ZIP/Postal Code
4004
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Sliven
ZIP/Postal Code
8800
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Sofia
ZIP/Postal Code
1233
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Stara Zagora
ZIP/Postal Code
6000
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Yambol
ZIP/Postal Code
8600
Country
Bulgaria
Facility Name
Novo Nordisk Investigational Site
City
Surrey
State/Province
British Columbia
ZIP/Postal Code
V3Z 2N6
Country
Canada
Facility Name
Novo Nordisk Investigational Site
City
Moncton
State/Province
New Brunswick
ZIP/Postal Code
E1G 1A7
Country
Canada
Facility Name
Novo Nordisk Investigational Site
City
Halifax
State/Province
Nova Scotia
ZIP/Postal Code
B3H 1V7
Country
Canada
Facility Name
Novo Nordisk Investigational Site
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8L 5G8
Country
Canada
Facility Name
Novo Nordisk Investigational Site
City
Hamilton
State/Province
Ontario
ZIP/Postal Code
L8M 1K7
Country
Canada
Facility Name
Novo Nordisk Investigational Site
City
London
State/Province
Ontario
ZIP/Postal Code
N5W 6A2
Country
Canada
Facility Name
Novo Nordisk Investigational Site
City
Baja
State/Province
Bács-Kiskun
ZIP/Postal Code
6500
Country
Hungary
Facility Name
Novo Nordisk Investigational Site
City
Budapest
ZIP/Postal Code
1089
Country
Hungary
Facility Name
Novo Nordisk Investigational Site
City
Budapest
ZIP/Postal Code
1106
Country
Hungary
Facility Name
Novo Nordisk Investigational Site
City
Budapest
ZIP/Postal Code
1132
Country
Hungary
Facility Name
Novo Nordisk Investigational Site
City
Debrecen
ZIP/Postal Code
4025
Country
Hungary
Facility Name
Novo Nordisk Investigational Site
City
Nyíregyháza
ZIP/Postal Code
4405
Country
Hungary
Facility Name
Novo Nordisk Investigational Site
City
Székesfehérvár
ZIP/Postal Code
8000
Country
Hungary
Facility Name
Novo Nordisk Investigational Site
City
Lublin
State/Province
Lubelskie
ZIP/Postal Code
20-044
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Lublin
State/Province
Lubelski
ZIP/Postal Code
20-538
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Krakow
State/Province
Malopolskie
ZIP/Postal Code
31-261
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Warszawa
State/Province
Mazowieckie
ZIP/Postal Code
00-710
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Warszawa
State/Province
Mazowieckie
ZIP/Postal Code
02-507
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Bialystok
State/Province
Podlaskie
ZIP/Postal Code
15-481
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Katowice
ZIP/Postal Code
40-752
Country
Poland
Facility Name
Novo Nordisk Investigational Site
City
Lisboa
ZIP/Postal Code
1250-230
Country
Portugal
Facility Name
Novo Nordisk Investigational Site
City
Matosinhos
ZIP/Postal Code
4464-513
Country
Portugal
Facility Name
Novo Nordisk Investigational Site
City
Porto
ZIP/Postal Code
4200-319
Country
Portugal
Facility Name
Novo Nordisk Investigational Site
City
Bardejov
ZIP/Postal Code
08501
Country
Slovakia
Facility Name
Novo Nordisk Investigational Site
City
Bytca
ZIP/Postal Code
014 01
Country
Slovakia
Facility Name
Novo Nordisk Investigational Site
City
Kosice
ZIP/Postal Code
04013
Country
Slovakia
Facility Name
Novo Nordisk Investigational Site
City
Povazska Bystrica
ZIP/Postal Code
01701
Country
Slovakia
Facility Name
Novo Nordisk Investigational Site
City
Presov
ZIP/Postal Code
080 01
Country
Slovakia
Facility Name
Novo Nordisk Investigational Site
City
Port Elizabeth
State/Province
Eastern Cape
ZIP/Postal Code
6001
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Bloemfontein
State/Province
Free State
ZIP/Postal Code
9301
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Johannesburg
State/Province
Gauteng
ZIP/Postal Code
1820
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Johannesburg
State/Province
Gauteng
ZIP/Postal Code
1827
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Johannesburg
State/Province
Gauteng
ZIP/Postal Code
2013
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Durban
State/Province
KwaZulu Natal
ZIP/Postal Code
4093
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Durban
State/Province
KwaZulu-Natal
ZIP/Postal Code
4001
Country
South Africa
Facility Name
Novo Nordisk Investigational Site
City
Umkomaas
State/Province
KwaZulu-Natal
ZIP/Postal Code
4170
Country
South Africa

12. IPD Sharing Statement

Plan to Share IPD
Yes
IPD Sharing Plan Description
According to the Novo Nordisk disclosure commitment on novonordisktrials.com
IPD Sharing URL
http://novonordisk-trials.com

Learn more about this trial

A Research Study to See How Semaglutide Helps People With Excess Weight and Type 2 Diabetes Lose Weight

We'll reach out to this number within 24 hrs